Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials
Top Cited Papers
- 6 April 2009
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 265 (5), 568-580
- https://doi.org/10.1111/j.1365-2796.2008.02062.x
Abstract
To study the evidence on the efficacy and safety of ezetimibe monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia. Systematic review and meta-analysis of randomized controlled trials (RCTs). Eleven electronic bibliographic databases covering the biomedical, scientific and grey literature were searched from inception and supplemented by contact with experts in the field. Two reviewers independently determined the eligibility of RCTs, with a minimum treatment duration of 12 weeks, which compared ezetimibe monotherapy (10 mg per day) with placebo. In the absence of data from clinical outcome trials, surrogate endpoints such as changes in lipid concentrations were used as indicators of clinical outcomes. A meta-analysis of eight randomized, double-blind, placebo-controlled trials (all 12 weeks) showed that ezetimibe monotherapy was associated with a statistically significant mean reduction in LDL cholesterol (from baseline to endpoint) of -18.58%, (95% CI: -19.67 to -17.48, P < 0.00001) compared with placebo. Significant (P < 0.00001) changes were also found in total cholesterol (-13.46%, 95% CI: -14.22 to -12.70), HDL cholesterol (3.00%, 95% CI: 2.06-3.94) and triglyceride levels (-8.06%, 95% CI: -10.92 to -5.20). Ezetimibe monotherapy appeared to be well tolerated with a safety profile similar to placebo. In a meta-analysis restricted to short-term trials in hypercholesterolaemia, significant potentially favourable changes in lipid and lipoprotein levels relative to baseline occurred with ezetimibe monotherapy. Further long-term studies with cardiovascular and other clinical outcome data are needed to assess the efficacy and safety of ezetimibe more fully.This publication has 37 references indexed in Scilit:
- Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluationHealth Technology Assessment, 2008
- European guidelines on cardiovascular disease prevention in clinical practice: Executive summaryAtherosclerosis, 2007
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)The American Journal of Cardiology, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Identifying patients at risk for coronary heart disease: implications from trials of lipid‐lowering drug therapyQJM: An International Journal of Medicine, 2000
- Assessing the Quality of Randomized Trials: Reliability of the Jadad ScaleControlled Clinical Trials, 1999
- Does blinding of readers affect the results of meta-analyses?The Lancet, 1997
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984